BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with:...B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%...This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival...Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials...Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Pediatric Acute Lymphoblastic Leukemia: Other Recommended regimens…Blinatumomab